Emerging drugs for hypogonadism

Bibliography

• PLYMATE SR: Hypogonadism in men: an overview. In: Androgens in Health and Disease. Bagatell CJ, Bremner W (Eds), Humana Press, New Jersey, USA (2003):45-76.
   Google Scholar
• NIESCHLAG E, SWERDLOFF R, BEHRE HM et al.: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int. J. Androl. (2005) 28(3):125-127.
   PubMed Web of Science ®Google Scholar
• ROSE K: Extent and Nature of Testosterone Use. Proceedings of the IOM committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Phoenix, AZ, USA (2003).
   Google Scholar
• BHASIN S, SINGH AB, MAC RP, CARTER B, LEE MI, CUNNINGHAM GR: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J. Androl. (2003) 24(3):299-311.
   PubMed Web of Science ®Google Scholar
• HARMAN SM, METTER EJ, TOBIN JD, PEARSON J, BLACKMAN MR; BALTIMORE LONGITUDINAL STUDY OF AGING: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. (2001) 86(2):724-731.
   PubMed Web of Science ®Google Scholar
• BAGATELL CJ, BREMNER WJ: Androgens in men – uses and abuses. N. Engl. J. Med. (1996) 334(11):707-714.
   PubMed Web of Science ®Google Scholar
• BREMNER WJ, VITIELLO MV, PRINZ PN: Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. (1983) 56(6):1278-1281.
   PubMed Web of Science ®Google Scholar
• PLYMATE SR, TENOVER JS, BREMNER WJ: Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J. Androl. (1989) 10(5):366-371.
   PubMed Web of Science ®Google Scholar
• DIVER MJ, IMTIAZ KE, AHMAD AM, VORA JP, FRASER WD: Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin. Endocrinol. (Oxf) (2003) 58(6):710-717.
   PubMed Web of Science ®Google Scholar
• WINTERS SJ, CLARK BJ: Testosterone synthesis, transport, and metabolism. In: Androgens in Health and Disease. Bagatell CJ, Bremner WJ (Eds), Humana Press, New Jersey, USA (2003):3-22.
   Google Scholar
• GOOREN LJ, BUNCK MC: Androgen replacement therapy: present and future. Drugs (2004) 64(17):1861-1891.
   PubMed Web of Science ®Google Scholar
• JUNKMANN K: Long-acting steroids in reproduction. Recent Prog. Horm. Res. (1957) 13:389-419; discussion 419-428.
   PubMedGoogle Scholar
• SNYDER PJ, LAWRENCE DA: Treatment of male hypogonadism with testosterone enanthate. J. Clin. Endocrinol. Metab. (1980) 51(6):1335-1339.
   PubMed Web of Science ®Google Scholar
• DOBS AS, MEIKLE AW, ARVER S, SANDERS SW, CARAMELLI KE, MAZER NA: Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. (1999) 84(10):3469-3478.
   PubMed Web of Science ®Google Scholar
• ARVER S, DOBS AS, MEIKLE AW et al.: Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin. Endocrinol. (Oxf) (1997) 47(6):727-737.
   PubMed Web of Science ®Google Scholar
• MACKEY MA, CONWAY AJ, HANDELSMAN DJ: Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum. Reprod. (1995) 10(4):862-865.
   PubMed Web of Science ®Google Scholar
• SCHUBERT M, MINNEMANN T, HUBLER D et al.: Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J. Clin. Endocrinol. Metab. (2004) 89(11):5429-5434.
   PubMed Web of Science ®Google Scholar
• VON ECKARDSTEIN S, NIESCHLAG E: Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a Phase II study. J. Androl. (2002) 23(3):419-425.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, ABSHAGEN K, OETTEL M, HUBLER D, NIESCHLAG E: Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies. Eur. J. Endocrinol. (1999) 140(5):414-419.
   PubMed Web of Science ®Google Scholar
• ZHANG GY, GU YQ, WANG XH, CUI YG, BREMNER WJ: A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J. Androl. (1998) 19(6):761-768.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, BANCROFT J, WU FC: The effects of exogenous testosterone on sexuality and mood of normal men. J. Clin. Endocrinol. Metab. (1992) 75(6):1503-1507.
   PubMed Web of Science ®Google Scholar
• HARLE L, BASARIA S, DOBS AS: Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin. Pharmacother. (2005) 6(10):1751-1759.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E, BUCHTER D, VON ECKARDSTEIN S, ABSHAGEN K, SIMONI M, BEHRE HM: Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin. Endocrinol. (Oxf) (1999) 51(6):757-763.
   PubMed Web of Science ®Google Scholar
• JONES TM, FANG VS, LANDAU RL, ROSENFIELD RL: The effects of fluoxymesterone administration on testicular function. J. Clin. Endocrinol. Metab. (1977) 44(1):121-129.
   PubMed Web of Science ®Google Scholar
• NADELL J, KOSEK J: Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch. Pathol. Lab. Med. (1977) 101(8):405-410.
   PubMed Web of Science ®Google Scholar
• PARADINAS FJ, BULL TB, WESTABY D, MURRAY-LYON IM: Hyperplasia and prolapse of hepatocytes into hepatic veins during longterm methyltestosterone therapy: possible relationships of these changes to the developement of peliosis hepatis and liver tumours. Histopathology (1977) 1(4):225-246.
   PubMed Web of Science ®Google Scholar
• WESTABY D, OGLE SJ, PARADINAS FJ, RANDELL JB, MURRAY-LYON IM: Liver damage from long-term methyltestosterone. Lancet (1977) 2(8032):262-263.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG EH, BEHRE M: Pharmacology and Clinical Uses of testosterone. In: Testosterone: Acition, Efficiency, Substitution. Springer-Verlag, New York, USA (1990):92-108.
   Google Scholar
• HORST HJ, HOLTJE WJ, DENNIS M, COERT A, GEELEN J, VOIGT KD: Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. Klin.Wochenschr. (1976) 54(18):875-879.
   PubMedGoogle Scholar
• MARIN P, HOLMANG S, JONSSON L et al.: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord. (1992) 16(12):991-997.
   PubMed Web of Science ®Google Scholar
• SCHUBERT M, BULLMANN C, MINNEMANN T, REINERS C, KRONE W, JOCKENHOVEL F: Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm. Res. (2003) 60(1):21-28.
   PubMed Web of Science ®Google Scholar
• GOOREN LJ: A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. (1994) 15(3):212-215.
   PubMed Web of Science ®Google Scholar
• SKAKKEBAEK NE, BANCROFT J, DAVIDSON DW, WARNER P: Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin. Endocrinol. (Oxf) (1981) 14(1):49-61.
   PubMed Web of Science ®Google Scholar
• MORALES A, JOHNSTON B, HEATON JP, LUNDIE M: Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J. Urol. (1997) 157(3):849-854.
   PubMed Web of Science ®Google Scholar
• KIM S, SNIPES W, HODGEN GD, ANDERSON F: Pharmacokinetics of a single dose of buccal testosterone. Contraception (1995) 52(5):313-316.
   PubMed Web of Science ®Google Scholar
• KORBONITS M, SLAWIK M, CULLEN D et al.: A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J. Clin. Endocrinol. Metab. (2004) 89(5):2039-2043.
   PubMed Web of Science ®Google Scholar
• DOBS AS, MATSUMOTO AM, WANG C, KIPNES MS: Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr. Med. Res. Opin. (2004) 20(5):729-738.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, VON ECKARDSTEIN S, KLIESCH S, NIESCHLAG E: Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7 – 10 years. Clin. Endocrinol. (Oxf) (1999) 50(5):629-635.
   PubMed Web of Science ®Google Scholar
• ARVER S, DOBS AS, MEIKLE AW, ALLEN RP, SANDERS SW, MAZER NA: Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J. Urol. (1996) 155(5):1604-1608.
   PubMed Web of Science ®Google Scholar
• MEIKLE AW, ARVER S, DOBS AS, SANDERS SW, RAJARAM L, MAZER NA: Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site – a clinical research center study. J. Clin. Endocrinol. Metab. (1996) 81(5):1832-1840.
   PubMed Web of Science ®Google Scholar
• MEIKLE AW, CARDOSO DE SOUSA JC, DACOSTA N, BISHOP DK, SAMLOWSKI WE: Direct and indirect effects of murine interleukin-2, gamma interferon, and tumor necrosis factor on testosterone synthesis in mouse Leydig cells. J. Androl. (1992)13(5):437-443.
   PubMed Web of Science ®Google Scholar
• JAIN P, RADEMAKER AW, MCVARY KT: Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J. Urol. (2000) 164(2):371-375.
   PubMed Web of Science ®Google Scholar
• WILSON DE, KAIDBURY K, BOIKE SC, JORKASKY DK: Use of topical corticosteroid cream in the pretreament of skin reactions associated with androderm testosterone transdermal system. Endocrine Soc. (1997) 79:P01-323.
   Google Scholar
• WANG C, BERMAN N, LONGSTRETH JA et al.: Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J. Clin. Endocrinol. Metab. (2000) 85(3):964-969.
   PubMed Web of Science ®Google Scholar
• STEIDLE C, SCHWARTZ S, JACOBY K et al.: AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. (2003) 88(6):2673-2681.
   PubMed Web of Science ®Google Scholar
• WANG C, CUNNINGHAM G, DOBS A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. (2004) 89(5):2085-2098.
   PubMed Web of Science ®Google Scholar
• WANG C, SWERDLOFF RS, IRANMANESH A et al.: Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin. Endocrinol. (Oxf) (2001) 54(6):739-750.
   PubMed Web of Science ®Google Scholar
• POPE HG Jr, COHANE GH, KANAYAMA G, SIEGEL AJ, HUDSON JI: Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160(1):105-111.
   PubMed Web of Science ®Google Scholar
• ROLF C, KNIE U, LEMMNITZ G, NIESCHLAG E: Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin. Endocrinol. (Oxf) (2002) 56(5):637-641.
   PubMed Web of Science ®Google Scholar
• MARBURY T, HAMILL E, BACHAND R, SEBREE T, SMITH T: Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm. Drug Dispos. (2003) 24(3):115-120.
   PubMed Web of Science ®Google Scholar
• MCNICHOLAS TA, DEAN JD, MULDER H, CARNEGIE C, JONES NA: A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. (2003) 91(1):69-74.
   PubMed Web of Science ®Google Scholar
• WANG C, SWERDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85(8):2839-2853.
   PubMed Web of Science ®Google Scholar
• KUHNERT B, BYRNE M, SIMONI M et al.: Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur. J. Endocrinol. (2005) 153(2):317-326.
   PubMed Web of Science ®Google Scholar
• GRAY A, FELDMAN HA, MCKINLAY JB, LONGCOPE C: Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. (1991) 73(5):1016-1025.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO AM: Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J. Gerontol. A Biol. Sci. Med. Sci. (2002) 57(2):M76-M99.
   Google Scholar
• MORLEY JE, KAISER FE, PERRY HM III et al.: Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism (1997) 46(4):410-413.
   PubMed Web of Science ®Google Scholar
• KAUFMAN JM, VERMEULEN A: Declining gonadal function in elderly men. Baillieres Clin. Endocrinol. Metab. (1997)11(2):289-309.
   PubMed Web of Science ®Google Scholar
• KAUFMAN J, VERMEULEN MA: The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. (2005) 26(6):833-876.
   PubMed Web of Science ®Google Scholar
• TENOVER JL: Testosterone and the aging male. J. Androl. (1997) 18(2):103-106.
   PubMed Web of Science ®Google Scholar
• NEGRO-VILAR A: Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. (1999) 84(10):3459-3462.
   PubMed Web of Science ®Google Scholar
• GAO W, REISER PJ, COSS CC et al.: Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 146(11):4887-4897.
   PubMed Web of Science ®Google Scholar
• HANADA K, FURUYA K, YAMAMOTO N et al.: Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. (2003) 26(11):1563-1569.
   PubMed Web of Science ®Google Scholar
• MARHEFKA CA, GAO W, CHUNG K et al.: Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. (2004) 47(4):993-998.
   PubMed Web of Science ®Google Scholar
• YIN D, GAO W, KEARBEY JD et al.: Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther. (2003) 304(3):1334-1340.
   PubMed Web of Science ®Google Scholar
• YIN D, HE Y, PERERA MA et al.: Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol. Pharmacol. (2003) 63(1):211-223.
   PubMed Web of Science ®Google Scholar
• EDWARDS JP, WEST SJ, POOLEY CL, MARSCHKE KB, FARMER LJ, JONES TK: New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino [3,2-g] quinolinone. Bioorg. Med. Chem. Lett. (1998) 8(7):745-750.
   PubMed Web of Science ®Google Scholar
• HWANG DJ, YANG J, XU H et al.: Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorg. Med. Chem. (2006) 14(19):6525-6538.
   PubMed Web of Science ®Google Scholar
• CADILLA R, TURNBULL P: Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr. Top. Med. Chem. (2006) 6(3):245-270.
   PubMed Web of Science ®Google Scholar
• SEGAL S, NARAYANAN R, DALTON JT: Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin. Investig. Drugs (2006) 15(4):377-387.
   PubMed Web of Science ®Google Scholar
• CHEN J, KIM J, DALTON JT: Discovery and therapeutic promise of selective androgen receptor modulators. Mol. Interv. (2005) 5(3):173-188.
   PubMed Web of Science ®Google Scholar
• CUMMINGS DE, KUMAR N, BARDIN CW, SUNDARAM K, BREMNER WJ: Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J. Clin. Endocrinol. Metab. (1998) 83(12):4212-4219.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, MARTIN CW, KUNG AW et al.: 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J. Clin. Endocrinol. Metab. (1999) 84(10):3556-3562.
   PubMed Web of Science ®Google Scholar
• SUVISAARI J, SUNDARAM K, NOE G et al.: Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men. Hum. Reprod. (1997) 12(5):967-973.
   PubMed Web of Science ®Google Scholar
• ANDERSON RA, WALLACE AM, SATTAR N, KUMAR N, SUNDARAM K: Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J. Clin. Endocrinol. Metab. (2003) 88(6):2784-2793.
   PubMed Web of Science ®Google Scholar
• SHAO TC, LI HL, KASPER S, MATUSIK R, ITTMANN M, CUNNINGHAM GR: Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Prostate (2006) 66(4):369-376.
   PubMed Web of Science ®Google Scholar
• VENKEN K, BOONEN S, VAN HERCK E et al.: Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone (2005) 36(4):663-670.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM GR, CORDERO E, THORNBY JI: Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA (1989) 261(17):2525-2530.
   PubMed Web of Science ®Google Scholar
• GUAY AT, BANSAL S, HEATLEY GJ: Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J. Clin. Endocrinol. Metab. (1995) 80(12):3546-3552.
   PubMed Web of Science ®Google Scholar
• GUAY AT, JACOBSON J, PEREZ JB, HODGE MB, VELASQUEZ E: Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int. J. Impot. Res. (2003) 15(3):156-165.
   PubMed Web of Science ®Google Scholar
• SHABSIGH A, KANG Y, SHABSIGN R et al.: Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J. Sex. Med. (2005) 2(5):716-721.
   PubMed Web of Science ®Google Scholar
• LEDER BZ, ROHRER JL, RUBIN SD, GALLO J, LONGCOPE C: Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J. Clin. Endocrinol. Metab. (2004) 89(3):1174-1180.
   PubMed Web of Science ®Google Scholar
• TAXEL P, KENNEDY DG, FALL PM, WILLARD AK, CLIVE JM, RAISZ LG: The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J. Clin. Endocrinol. Metab. (2001) 86(6):2869-2874.
   PubMed Web of Science ®Google Scholar
• RAMAN JD, SCHLEGEL PN: Aromatase inhibitors for male infertility. J. Urol. (2002) 167(2 Pt 1):624-629.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN RB, MATSUMOTO AM, BREMNER WJ: Idiopathic hypogonadotropic hypogonadism with anosmia (Kallmann’s syndrome). Endocrinologist (1992) 2:332.
   Google Scholar
• GOOREN L: Hypogonadotropic hypogonadal men respond less well to androgen substitution treatment than hypergonadotropic hypogonadal men. Arch. Sex. Behav. (1988)17(3):265-270.
   PubMed Web of Science ®Google Scholar
• JOHNSEN SG: Maintenance of spermatogenesis induced by HMG treatment by means of continuous HCG treatment in hypogonadotrophic men. Acta Endocrinol. (Copenh) (1978) 89(4):763-769.
   PubMedGoogle Scholar
• VICARI E, MONGIOI A, CALOGERO AE et al.: Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism-long-term follow-up. Int. J. Androl. (1992) 15(4):320-329.
   PubMed Web of Science ®Google Scholar
• LIU PY, WISHART SM, HANDELSMAN DJ: A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J. Clin. Endocrinol. Metab. (2002) 87(7):3125-3135.
   PubMed Web of Science ®Google Scholar
• CHOI SK, HAN SW, KIM DH, DE LIGNIERES B: Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J. Urol. (1993) 150(2 Pt 2):657-660.
   PubMed Web of Science ®Google Scholar
• SWERDLOFF R, WANG SC: Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillieres Clin. Endocrinol. Metab. (1998) 12(3):501-506.
   PubMed Web of Science ®Google Scholar
• WANG CR, SWERDLOFF S: Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J. Clin. Endocrinol. Metab. (2002) 87(4):1462-1466.
   PubMed Web of Science ®Google Scholar
• SCHAISON G, COUZINET B: Percutaneous dihydrotestosterone (DHT) treatment. In: Testosterone: Action, Deficiency, Substitution (Volume 2). Nieschlag E, Behre HM (Eds). Spring-Verlag, Berlin, Germany (1998) 2(1):423-436.
   Google Scholar
• DE LIGNIERES B: Transdermal dihydrotestosterone treatment of ‘andropause’. Ann. Med. (1993) 25(3):235-241.
   PubMed Web of Science ®Google Scholar
• LY LP, JIMENEZ M, ZHUANG TN, CELERMAJER DS, CONWAY AJ, HANDELSMAN DJ: A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J. Clin. Endocrinol. Metab. (2001) 86(9):4078-4088.
   PubMed Web of Science ®Google Scholar
• KUNELIUS P, LUKKARINEN O, HANNUKSELA ML, ITKONEN O, TAPANAINEN JS: The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J. Clin. Endocrinol. Metab. (2002) 87(4):1467-1472.
   PubMed Web of Science ®Google Scholar
• SNYDER PJ: Hypogonadism in elderly men-what to do until the evidence comes. N. Engl. J. Med. (2004) 350(5):440-442.
   PubMed Web of Science ®Google Scholar
• CALOF OM, SINGH AB, LEE ML et al.: Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A Biol. Sci. Med. Sci. (2005) 60(11):1451-1457.
   PubMed Web of Science ®Google Scholar
• BHASIN S, CUNNINGHAM GR, HAYES FJ et al.: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. (2006) 91(6):1995-2010.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E, BEHRE HM: Testosterone: Action, Deficiency, Substitution (Vol. 3). Cambridge University Press, Cambridge, UK (2004).
   Google Scholar
• BHASIN S, CALOF OM, STORER TW et al.: Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nature Clin. Pract. (2006) 2(3):146-159.
   Google Scholar